

ASX ANNOUNCEMENT MARKET RELEASE

20 February 2025

SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(E) OF THE CORPORATIONS ACT 2001

Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company focused on commercialising its patented AI platform that detects key coronary artery disease imaging markers, provides this notice in accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

On 20 February 2025, the Company issued a total of 6,798,498 fully paid ordinary shares pursuant to the share placement announced to ASX on 14 February 2025, without disclosure under Part 6D.2 of the Corporations Act. Artrya gives notice under section 708A(5)(E) of the Act that:

1. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2. As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
3. As at the date of this notice, there is no excluded information (in accordance with the requirements of subsections 708A(7) and (8) of the Corporations Act.

Artrya Limited

Kevin Hart

Company Secretary

This announcement was approved for release by the Company Secretary.

For further information please contact:

Investor Enquiries:

Danny Younis

+61 420 293 042

danny.younis@automicgroup.com.au

Media Relations:

Rama Razy

+61 498 440 142

rama.razy@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com